ENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal Spray

2022-05-11T12:00:00Z

SYDNEY, Australia, May 11, 2022 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pan-antiviral prophylaxis in at-risk populations and pandemic preparedness, has been selected to join BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA), a component of the U.S. Department of Health and Human Services. ENA Respiratory is the first Australian company to be selected to join Blue Knight.

Blue Knight offers a scientific and technological ecosystem for innovative, early-stage companies to develop strategically aligned technologies that aim to combat health threats and emerging infectious diseases. ENA Respiratory’s selection highlights the urgent unmet need for therapies that could help the body respond faster to a broad range of respiratory viral infections and reduce the risk of hospitalization or complications. As a Blue Knight company, ENA Respiratory will benefit from mentorship from experts from BARDA, the Johnson & Johnson Family of Companies, and a global network of innovators who could provide critical insight and support throughout INNA-051 development.

ENA Respiratory’s self-administered nasal spray INNA-051 product is designed with the aim to stimulate the innate immunity in the nose, which is the preferential site of initial infection and replication of most respiratory viruses. Pre-clinical research demonstrates that INNA-051 has pan-antiviral potential with efficacy against a variety of respiratory viruses, including SARS-CoV-2, influenza, and the common cold rhinovirus.

“As we continue to advance the development of INNA-051, we look forward to working alongside BARDA, industry leaders, and other innovative companies with the aim to address emerging health threats and better protect our global community against infectious diseases,” said Christophe Demaison, Ph.D., CEO of ENA Respiratory.

ENA Respiratory is a virtual resident within JLABS, a premier life science incubator program.

Recently, ENA Respiratory began a Phase 2a influenza challenge pre-exposure prophylaxis study of INNA-051. It was found to be well-tolerated in a Phase 1 study, and Phase 1 data will be presented at the 2022 American Thoracic Society International Conference (May 13- 18, San Francisco).

Notes to Editors

If you would like to arrange an interview, please contact:

About ENA Respiratory and INNA-051

ENA Respiratory is aiming to transform the prevention of respiratory viral infections in populations at-risk of complications. The company is based in Melbourne and Sydney, Australia and it has secured a Series A funding from Brandon Capital Partners’ managed funds, the Minderoo Foundation, and Uniseed.

INNA-051 is a potent innate immune TLR2/6 agonist. It is being developed for intranasal delivery to target the preferential site of initial infection and replication of most respiratory viruses, including SARS-CoV-2 and influenza. Fast-acting and inducing a durable biologic response supporting weekly administration, INNA-051 works by recruiting innate immune cells and priming epithelial cells of the nasal mucosa to respond more quickly to infections, rapidly eliminating viruses and other pathogens before they spread throughout the body. INNA-051 and close analogues have been shown in preclinical studies to be effective against multiple respiratory viruses, including SARS-CoV-2, influenza (H1N1 and seasonal H3N2), and rhinovirus.

Key features of INNA-051 intranasal administration include limited minimal or no systemic bioavailability, minimal or no systemic pro-inflammatory cytokine release, no direct type I interferon upregulation which is known to be associated with fever in humans, durable immune response supporting weekly administration, and compatibility with vaccine and intranasal corticosteroids.

For more information, please visit https://enarespiratory.com

 


Globe Newswire News

RSS Australian Mining Releases

  • Xanadu Mines Date of 2024 Annual General Meeting
    TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (“Xanadu” or “the Company”) is pleased to advise that in accordance with ASX Listing Rule 3.13.1, Xanadu will hold its 2024 Annual General Meeting on: Date: Thursday, 23 May 2024Time: 11:00am AESTLocation: Victoria Hotel  215 Little Collins Street  Melbourne Victoria 3000  Australia    The closing date for the […]
  • Drilling Underway at Red Mountain Project
    Figure 1 Map of Mongolia, showing location of the Red Mountain Mining Lease. Figure 2 The Red Mountain Mining Lease with designed drill holes and target locations. Figure 3 Exploration drilling has commenced at Red Mountain. Figure 4 Target 33 showing previous drilling and trenching(2) and planned drilling 2024. Figure 5 Target 10 showing previous […]
  • Kharmagtai Water Supply Drilling Program Recommences
    Figure 1 PFS Water Drilling in ZUK Basin Figure 2 Drilling Water Monitoring Hole at ZUK Basin TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (Xanadu, XAM or the Company) is pleased to announce that the hydrological drilling program has re-commenced for the Kharmagtai Pre-Feasibility Study (PFS), which is […]
  • MCB Project Mining Permit granted by Philippine Government
    HIGHLIGHTS The Philippine Department of Environment and Natural Resources has approved MCB’s mining permit on 15 March 2024, valid for 25 years and renewable for another 25 years. The permit grants the Company exclusive rights to undertake rational exploration, development, and commercial production of copper and associated minerals.The issuance of the mining permit will enable […]
  • Xanadu Mines Ltd (ASX Code: XAM) Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)
    TORONTO, March 06, 2024 (GLOBE NEWSWIRE) -- This notice is given by Xanadu Mines Ltd (ACN 1144 249 026) (Xanadu Mines or the Company) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Act). Xanadu Mines advises that on 4 March 2024, it issued 15,185,328 fully paid ordinary shares at a price of $0.055 per […]
  • Encouraging oxide leach recovery for copper & gold at Kharmagtai
    Figure 1 Oxide Column Leach at DMPS Labs Figure 2 Oxide Layer Over White Hill & Stockwork Hill – Cross Section Looking West Figure 3 Collar locations for drill holes sampled in metallurgical testwork TORONTO, March 06, 2024 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (Xanadu, XAM or the Company) is pleased […]
  • Completion of Placement to Zijin Mining
    TORONTO, March 04, 2024 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX:XAM, TSX:XAM) (Xanadu or the Company) is pleased to announce that the placement of 15,185,328 fully paid ordinary shares to Jinping (Singapore) Mining Pte Ltd, a wholly owned indirect subsidiary of Zijin Mining Group Co. Ltd (Zijin), at an issue price of A$0.055 per share, […]
  • Completion of Placement to Zijin Mining
    TORONTO, March 04, 2024 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX:XAM, TSX:XAM) (Xanadu or the Company) is pleased to announce that the placement of 15,185,328 fully paid ordinary shares to Jinping (Singapore) Mining Pte Ltd, a wholly owned indirect subsidiary of Zijin Mining Group Co. Ltd (Zijin), at an issue price of A$0.055 per share, […]
  • Metallurgical Tests at Kharmagtai Show Strong Sulphide Rougher Flotation Recovery
    Figure 1 Copper Grade vs Rougher Recovery Figure 2 Conventional flowsheet (simplified) Figure 3 Copper Rougher Recovery versus Grind Size Figure 3 Collar locations for drill holes sampled in metallurgical test work TORONTO, March 04, 2024 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (Xanadu, XAM or the Company) is pleased to provide […]
  • Perseus Mining Half Year Results
    perth, Feb. 23, 2024 (GLOBE NEWSWIRE) -- PERSEUS MINING BOOSTS AFTER TAX HY PROFIT BY 21% TO US$165M & INCREASES NET CASH & BULLION TO US$642M Perth, Western Australia/February 23, 2024/Mid-tier, African focused gold producer, developer and explorer, Perseus Mining Limited (ASX/TSX:PRU) has reported material improvements across all key financial metrics including revenue, EBITDA, profit […]

Stay up to date

Get notified about the latest gold mining news as soon as it happens or choose daily or weekly deliveries.
GET Newsletters
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram